AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy
Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today...
PersonGen BioTherapeutics
Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that its joint venture with...
CATUG Biotechnology Partners with PersonGen to Advance Global CAR-T Cell Therapies
China-based CATUG Biotechnology (Suzhou) Co., Ltd. has entered into a partnership with fellow Suzhou firm...
PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy
The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...